BERRINO L

Last name: BERRINO L

1993 (v1)

Publication

Metadata-only

3-(Arylamino)-6,7-dihydro-6-methylpyrano[4,3-c]pyrazol-4(1H or 2H)-ones with antipyretic, analgesic, antiarrhythmic, hypotensive and other activities.

BRUNO, OLGA RANISE, ANGELO SCHENONE, SILVIA

The synthesis of 3-(arylamino)-6,7-dihydro-6-methylpyrano[4,3-c]pyrazol-4(1H or 2H)-ones [I, R = (un)substituted Ph] by reaction of N-aryl-5,6-dihydro-4-hydroxy-6-methyl-2-oxo-2H-pyrano-3-carbothioamides with hydrazine is described. Some compds. showed remarkable antipyretic, analgesic, antiarrhythmic and hypotensive activity in rats or mice,...

Uploaded on: March 27, 2023
1996 (v1)

Publication

Metadata-only

Synthesis and pharmacological profile of novel N-substituted N-[5H-[1]benzopyrano[4,3-d]pyrimidin-2-YL]-N-methylglycinamides.

BRUNO, OLGA SCHENONE, SILVIA RANISE, ANGELO

No description

Uploaded on: April 14, 2023
1987 (v1)

Publication

Metadata-only

Esters of N-methyl-N-(2-hydroxyethyl or 3-hydroxypropyl)-1,3,3-trimethylbicyclo [2.2.1]heptan-2-endo-amine with hypotensive activity

BONDAVALLI, FRANCESCO BRUNO, OLGA Mariani E

No description

Uploaded on: March 31, 2023
2011 (v1)

Publication

Metadata-only

Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors

Morgillo F Cascone T D'Aiuto E

No description

Uploaded on: April 14, 2023
2012 (v1)

Publication

Metadata-only

Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells

Troiani T Vecchione L Martinelli E

Background:MEK is activated in ∼40% colorectal cancer (CRC) and 20-30% non-small cell lung cancer (NSCLC). Selumetinib is a selective inhibitor of MEK1/2, which is currently in clinical development.Methods:We evaluated the effects of selumetinib in vitro and in vivo in CRC and NSCLC cell lines to identify cancer cell characteristics correlating...

Uploaded on: April 14, 2023
2013 (v1)

Publication

Metadata-only

Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells

Troiani T Martinelli E Napolitano S

PURPOSE: Although cetuximab, an anti-EGF receptor (EGFR) monoclonal antibody, is an effective treatment for patients with KRAS wild-type metastatic colorectal cancer (mCRC), its clinical use is limited by onset of resistance. EXPERIMENTAL DESIGN: We characterized two colorectal cancer models to study the mechanisms of acquired resistance to...

Uploaded on: April 14, 2023

BERRINO L

Recent uploads